HOLLENCREST CAPITAL MANAGEMENT - INTERCEPT PHARMACEUTICALS IN ownership

Quarter-by-quarter ownership
HOLLENCREST CAPITAL MANAGEMENT ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$278,100
+67.6%
15,0000.0%0.03%
+82.4%
Q2 2023$165,900
-17.6%
15,0000.0%0.02%
-22.7%
Q1 2023$201,450
+8.6%
15,0000.0%0.02%
-4.3%
Q4 2022$185,550
-11.2%
15,0000.0%0.02%
-11.5%
Q3 2022$209,000
+1.0%
15,0000.0%0.03%
+8.3%
Q2 2022$207,000
-15.2%
15,0000.0%0.02%
+9.1%
Q1 2022$244,0000.0%15,0000.0%0.02%
+15.8%
Q4 2021$244,00015,0000.02%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2023
NameSharesValueWeighting ↓
Sarissa Capital Management LP 635,300$53,308,00010.69%
Senvest Management, LLC 976,127$81,907,0005.65%
Melqart Asset Management (UK) Ltd 390,600$32,775,0002.80%
Asymmetry Capital Management, L.P. 25,918$2,175,0002.14%
Elk Creek Partners, LLC 386,397$32,423,0001.78%
BB BIOTECH AG 545,719$45,791,0001.32%
ALTRINSIC GLOBAL ADVISORS LLC 383,166$32,151,0001.27%
DLD Asset Management, LP 129,000$10,824,0000.82%
Opus Point Partners Management, LLC 3,998$335,0000.73%
Virtus ETF Advisers LLC 8,970$753,0000.67%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders